Compound T Phase 1

Tirzepatide was developed to fight type 2 diabetes, but has additionally been shown to protect the cardiovascular system. Tirzepatide is a synthetic derivative of gastric inhibitory polypeptide (GIP) that has simultaneous glucagon-like peptide-1 (GLP-1) functionality as well. This combination allows Tirzepatide to lower blood glucose levels, increase insulin sensitivity, boost feelings of satiety.